和人 西尾
About
In The Last Decade
和人 西尾
2 papers receiving 490 citations
Peers
Comparison fields: 5 of 55
- Cancer Research 435
- Molecular Biology 429
- Oncology 17
- Surgery 15
- Immunology 15
Countries citing papers authored by 和人 西尾
This map shows the geographic impact of 和人 西尾's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by 和人 西尾 with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites 和人 西尾 more than expected).
Fields of papers citing papers by 和人 西尾
This network shows the impact of papers produced by 和人 西尾. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by 和人 西尾. The network helps show where 和人 西尾 may publish in the future.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | mTOR阻害薬などのシグナル伝達と阻害薬の開発動向 (特集 分子標的治療薬で変わるがん治療) -- (最新の分子標的治療) | 0 |
| 2 | What's going on ゲノム MicroRNA expression profiles classify human cancers. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, Downing JR, Jacks T, Horvitz HR, Golub TR. Nature. 2005; 435: 834-8. PMID: 15944708.--マイクロRNAプロファイルが癌の診断に利用できる可能性を示した論文 | 495 |
| 3 | What's going on ゲノム Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Gerber HP, Ferrara N. Cancer Res. 2005;65:671-80. PMID:15705858. ベバシズマブの単剤使用または細胞傷害性薬剤との併用使用における薬理学・薬力学的評価を述べた論文 | 1 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.